Investor Relations
NASDAQ: PNT
POINT has built a platform to accelerate the next-generation of radiopharmaceuticals with an industry-leading pipeline, in-house manufacturing capabilities, and redundant supply of rare medical isotopes. The management team brings decades of combined experience in radiopharmaceutical clinical development and manufacturing, including 40+ clinical trials, 12 drug approvals, and 8 GMP radiopharmaceutical facilities, and has leveraged prior relationships to assemble one of the industry’s most resilient radioisotope supply chains. The company’s 100%-owned, 80,000 sq ft facility has capacity to commercially supply both North America and Europe for large volume indications. POINT has two late-stage programs one of which is PNT2002, currently being evaluated in the Phase 3 SPLASH study targeting mCRPC, which could lay the cornerstones of the company’s radiopharmaceutical platform. POINT also has an exciting early-stage pipeline which includes a best-in-class FAP-α targeted radioligand PNT2004, a potential pan-cancer target.
Investor Presentations
Supplementary Presentations:
POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates. Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH registrational trial, with top line data expected in the second half of 2023.
POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinical trial for the PSMA-targeted PNT2002 program is not experiencing any manufacturing or drug supply issues or delays.
Events Calendar
2023 UPCOMING EVENTS
April 3: Jefferies Radiopharma Innovation Summit
April 26: 2023 Bloom Burton & Co. Healthcare Investor Conference
- Format: Presentation and 1x1 Meetings
- Webcast link available here
2023 PAST EVENTS
February 7: Guggenheim 5th Annual Oncology Conference
- Format: Fireside Chat and 1x1 Meetings
- Webcast link available here
February 16: SVB Securities Global Biopharma Conference
- Format: Fireside Chat and 1x1 Meetings
- Webcast link available here
March 7: Cowen 43rd Annual Health Care Conference
- Format: GI/GU Oncology Panel Discussion and 1x1 Meetings
- Time: 12:50pm ET
- Webcast link available here
March 13: Oppenheimer 33rd Annual Healthcare Investor Conference
- Format: Fireside Chat and 1x1 Meetings
March 27: FY2022 Financial Results
VIEW 2022 PAST EVENTS
Stock, Financials & Governance
Financial Reports
Board of Directors
Management
Stock Price
SEC Filings
Section 16 Filings
Governance Documents
Audit Committee Charter
Code of Business Conduct and Ethics
Whistleblower Line Information
Compensation Committee Charter
Corporate Governance Guidelines
Nominating and Corporate Governance Committee Charter
Analyst Coverage
Berenberg - Zhiqiang Shu
Brookline - Kemp Dolliver
Guggenheim - Charles Zhu
Jefferies - Suji Jeong
JonesTrading - Justin Walsh
Oppenheimer - Jeff Jones
Piper Sandler - Ted Tenthoff
Raymond James - Rahul Sarugaser
SVB Securities - Faisal Khurshid
TD Cowen - Boris Peaker
Truist - Nicole Germino
William Blair - Andy Hsieh
Please note, this list of analyst coverage may not complete or up to date. Any opinions, estimates or forecasts regarding performance made by analysts do not represent POINT Biopharma or its management team.
Contact
Investor
Relations
1-833-544-2637 x800Please do not submit any private or confidential information using this form. Fields marked with an asterisk (*) are required.
Your submission has been received!